1. Key study characteristics.
Study | Measure of restlessness | Comparator | IV or oral iron | Type of iron | Baseline iron status |
Study population (if RLS plus another condition) |
Time of assessment used |
Allen 2011 | IRLS | Placebo | IV | Ferric carboxymaltose | Not an inclusion/exclusion criterion (unless > 300 ng/mL); mean ferritin 40.6 ng/mL |
23 days | |
Cho 2016 | IRLS | Placebo | IV | Ferric carboxymaltose | Not an inclusion/exclusion criterion (unless > 300 ng/mL); mean ferritin 61.4 ng/mL |
4 weeks | |
Davis 2000 | Not measured | Placebo | Oral | Ferrous sulfate | Excluded if haemoglobin < 10 g/dL; mean ferritin 117.7 ng/mL | 12‐14 weeks | |
Deng 2016 | IRLS | Placebo | IV | Iron sucrose | For inclusion, serum ferritin < 200 ng/mL and transferrin saturation < 20% | Uremia on haemodialysis at least 1 year | 2 weeks |
Earley 2009 | IRLS | Placebo | IV | Iron sucrose | Excluded if haemoglobin < 12 d/dL; mean ferritin 75.2 ng/mL | 2 weeks | |
Grote 2009 | IRLS | Placebo | IV | Iron sucrose | For inclusion, serum ferritin < 45 ng/mL | 3 weeks | |
Lee 2014 | IRLS | Pramipexole | Oral | Ferrous sulfate | For inclusion, serum ferritin 15‐50 ng/mL | 12 weeks | |
Sloand 2004 | University of Rochester | Placebo | IV | Iron dextrose | Not an inclusion/exclusion criterion; median ferritin 136.3 ng/mL | End‐stage renal disease on dialysis |
2 weeks |
Trenkwalder 2017 | IRLS | Placebo | IV | Ferric carboxymaltose | For inclusion, serum ferritin < 75 ng/mL or both ferritin 75‐300 ng/mL and transferrin saturation < 20% | 4 weeks | |
Wang 2009 | IRLS | Placebo | Oral | Ferrous sulfate | For inclusion, serum ferritin 15‐75 ng/mL | 12 weeks |
IRLS: International Restless Legs Scale IV: intravenous